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Abstract 
Background: Simultaneous polydrug use (SPU) may repre-
sent a greater incremental risk factor for human health than 
concurrent polydrug use (CPU). However, few studies have 
examined these patterns of use in relation to health issues, 
particularly with regard to the number of drugs used.
Methods: In the present study, we have analyzed data 
from a representative sample of 5734 young Swiss males 
from the Cohort Study on Substance Use Risk Factors. 
Exposure to drugs (i.e., alcohol, tobacco, cannabis, and 15 
other illicit drugs), as well as mental, social and physical 
factors, were studied through regression analysis.
Results: We found that individuals engaging in CPU 
and SPU followed the known stages of drug use, involv-
ing initial experiences with licit drugs (e.g., alcohol and 
tobacco), followed by use of cannabis and then other illicit 
drugs. In this regard, two classes of illicit drugs were iden-
tified, including first uppers, hallucinogens and sniffed 
drugs; and then “harder” drugs (ketamine, heroin, and 
crystal meth), which were only consumed by polydrug 
users who were already taking numerous drugs. Moreover, 
we observed an association between the number of drugs 
used simultaneously and social issues (i.e., social conse-
quences and aggressiveness). In fact, the more often the 
participants simultaneously used substances, the more 
likely they were to experience social problems. In con-
trast, we did not find any relationship between SPU and 
depression, anxiety, health consequences, or health.
Conclusions: We identified some associations with SPU 
that were independent of CPU. Moreover, we found that 
the number of concurrently used drugs can be a strong 
factor associated with mental and physical health, 
although their simultaneous use may not significantly 
contribute to this association. Finally, the negative effects 
related to the use of one substance might be counteracted 
by the use of an additional substance.
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Introduction
Substance use disorder represents the most prevalent form 
of psychopathology in young adults (1, 2). Although it is 
well known that single drug use is rare (3–7), there have 
been few studies investigating polydrug use [i.e., the inges-
tion of more than one drug (3)]. Indeed, polydrug use is 
associated with a unique set of consequences (8), includ-
ing psychological morbidity/pathology (9–11), health risk 
behaviors (12) [e.g., HIV risk-taking (5)], difficulties engag-
ing in drug-abuse therapy (13), and worse outcomes fol-
lowing drug-abuse treatment (14). Moreover, some studies 
indicated that the abuse of a higher number of substances 
was associated with more severe health outcomes (15–18).
Two forms of polydrug use were described in litera-
ture, namely, concurrent and simultaneous (19). Con-
current polydrug use (CPU) refers to the use of two or 
more substances within a given time period. Meanwhile, 
simultaneous polydrug use (SPU) is the use of two or 
more substances at the same time, on a single occasion 
(20). SPU is considered a subset of CPU (21). Furthermore, 
SPU was found to be a key characteristic of the substance 
use patterns associated with many drug users, especially 
teenagers and young adults (1, 22–24). Moreover, studies 
demonstrated that SPU posed greater health risk than 
CPU (21). For example, simultaneous polydrug users 
reported more drug use-related problems than concurrent 
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polydrug users (21). Those engaging in SPU also displayed 
more social problems/consequences, psychosocial dis-
tress (e.g., depression) (19, 20), anxiety (19), and health 
problems (19, 20, 25). In addition, the risk of injury, poi-
soning, overdose (26), or suicide (25) was higher during 
SPU. Similarly, SPU led to an increased likelihood for later 
substance-related problems among teenagers (27).
The present investigation addresses some of the limi-
tations of earlier studies within this field. First of all, few 
studies compared CPU and SPU (21, 25). Second, these 
studies did not thoroughly investigate the impact of the 
number of drugs simultaneously used, a variable that 
reflected the level of severity of drug use in studies of 
CPU (15). Notably, the number of drugs used may be more 
important than the type of drugs used for the prediction 
of first suicide attempts (17). However, there may be a 
methodological problem when studying SPU, because it 
can be confounded with CPU (i.e., the more drugs people 
use simultaneously, the more drugs they must use concur-
rently). For this reason, some studies comparing SPU and 
CPU (21, 25) did not assess the associations of SPU with 
variables while controlling for CPU. Another limitation of 
past studies is that they focused on select substances, such 
as alcohol, tobacco, cannabis, and specific illicit drugs. 
Therefore, no previous study has investigated polydrug use 
patterns while considering a comprehensive list of drugs.
The aims of this study were to examine the patterns 
of CPU and SPU in relation to a wide variety of drugs (18 
drugs) and to determine the additional associations of 
SPU with health (i.e., relevant outcomes identified in pre-
vious studies on polydrug use in terms of mental/physi-
cal health, social problems and consequences) following 
adjustment for CPU. Although this cross-sectional study 
did not allow us to define causality, regression models 
were used to test associations between health and SPU 
after adjusting for several factors, including CPU.
Materials and methods
Subjects
The data for this study were obtained from the Cohort Study on Sub-
stance Use Risk Factors (C-SURF). C-SURF is an ongoing, longitudinal 
study designed to assess substance use patterns and related conse-
quences in young Swiss men. Enrollment took place between August 
23, 2010 and November 15, 2011 in three of the six army  recruitment 
centers located in Lausanne (French-speaking), and Windisch 
and Mels (German-speaking). These three centers covered 21 of 26 
 cantons in Switzerland, including all French-speaking cantons. In 
Switzerland, army service is compulsory. Thus, all young men at 
around 20 years of age were eligible for inclusion in the study. Our 
cohort was highly representative of young Swiss men. Moreover, this 
study was approved by the Ethics Committee for Clinical Research of 
the Lausanne University Medical School and followed the Helsinki 
declaration.
Of the 13,245 conscripts informed about the study, 7563 gave 
written consent to participate, and 5990 filled in the baseline ques-
tionnaire. This analysis was performed on baseline data only. The 
study focused on the 5636 participants who had used at least one 
drug during the past 12 months, including alcohol (94.1% of the sam-
ple). Subjects with missing values related to outcome variables were 
not considered in the analysis. Thus, the final study cohort included 
5319 participants (94.4% of the sample). More information about sam-
pling and non-response can be found in Studer et al. (28). Early re-
spondents (responses obtained without extra effort) were compared 
to late respondents (those responses acquired through increased 
efforts, i.e., encouraging telephone calls), and non- respondents 
(those who answered a 5-min questionnaire on substance use dur-
ing the enrollment phase of the C-SURF). Early respondents were less 
likely to be either substance users or heavy users in comparison to 
late respondents, and non-respondents showed generally higher pat-
terns of substance use than late respondents (excluding alcohol use). 
Therefore, using late respondents greatly reduced the magnitude of 
the non-response bias, even if it was insufficient to free survey esti-
mates from the risk of non-response bias. However, differences be-
tween respondents and non-respondents were small and significant 
only because of the large sample size (n = 11,819).
Measures
CPU
CPU was assessed by asking participants whether they used specific 
drugs during the past 12 months. Each drug was coded as “used” 
or “non-used”. The drugs included: 1) alcohol; 2) tobacco; 3) can-
nabis; 4) hallucinogens, magic mushrooms, psilocybin, peyote, 
or mescaline; 5) other hallucinogens [lysergic acid diethylamide 
(LSD), phencyclidine (PCP)/angeldust, 2-CB, or 2-CI]; 6) salvia divi-
norum; 7) speed; 8) amphetamine, methamphetamine, or ampheta-
minsulfate (e.g., Dexedrine, Benzedrine); 9) crystal meth (Ice); 10) 
poppers (amyl nitrite, butyl nitrite); 11) solvent sniffing [e.g., glue, 
solvent, or gas (benzin, ether, toulol, trichloroethylene, nitrous ox-
ide, etc.)]; 12) ecstasy, 3,4-methylenedioxy-N-methylamphetamine 
(MDMA); 13) cocaine, crack, or freebase; 14) heroin; 15) ketamine 
(Special K) or DXM; 16) gamma-hydroxybutyric acid (GHB)/gamma-
butyrolactone (GBL)/I-4 Butanediol (BDB); 17) research chemicals 
(e.g., mephedrone, butylone, or methedrone); and 18) spice or simi-
lar substances. The global CPU score was determined by summing 
up all the drug categories used during the past 12 months (licit and 
illicit drugs combined, total score from 1 to 18, each positive category 
counted as “1” in the total score).
SPU
The co-use of drugs was assessed by questioning participants about 
the drugs that they combined during the past 12 months. Specifically, 
individuals were asked to divulge the usual number of drugs they 
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used on a usual occasion (“usual SPU”), and the maximum number 
of drugs that they had combined (“maximum SPU”). The drug cat-
egories used for this assessment were the same as those used for CPU 
scoring. Two global SPU scores were determined (i.e., “usual SPU” 
and “maximum SPU”) by summing the total drugs used (licit and il-
licit drugs combined, total score from 0 to 18, each category counted 
as “1” for the total scores).
Mental, social, and physical factors
Anxiety and aggressiveness
In order to assess anxiety and aggressiveness, two subscales from 
the Zuckerman-Kuhlmann Personality Questionnaire (ZKPQ-50-cc) 
(29) were used, namely, neuroticism/anxiety and aggression/hos-
tility. The participants were asked to agree or disagree with each 
statement. A mean score was computed for each subscale (anxiety: 
α = 0.73, aggressiveness: α = 0.56).
Depression
Depression level was determined using the Major Depressive Inven-
tory (MDI) from the International Statistical Classification of Diseases 
and Related Health Problems (ICD-10) by the World Health Organiza-
tion (WHO) (30, 31). This is a 10-item questionnaire that screens an-
swers on a 6-point scale from “never” (0) to “all the time” (5). A mean 
score was computed (α = 0.91). A continuous scale (ranging from 0 to 
50) was used instead of a cutoff value in order to better capture vari-
ability across the range of depression symptoms.
Mental and physical health
The Short Form Health Survey (SF-12) was used to assess mental and 
physical health (32) based on two subscales, namely, mental/social 
health and physical health. The subscale scores were computed ac-
cording to the standard system, yielding two composite scores, which 
ranged from “0” (health problem) to “100” (no health problem). SF-12 
primarily covered sadness, nervousness, and depression.
Consequences
A total of 15 consequences were selected from standard instruments 
(33–36). However, these items were not explicitly substance related, 
and resulted in different associations compared with consequences 
that can be causally attributed to substances. Included items were 
related to social, personal, and health consequences. Each conse-
quence was coded “0” if it had not occurred in the past 12 months 
and “1” if it had taken place at least once during the past 12 months. 
Two mean scores of consequences were computed. The first score 
was related to social consequences, including physical fights, prob-
lems with family/friends, poor performance at school/work, theft, 
trouble with the police, regretted sexual intercourse, or damage to 
property. The second score was related to health consequences, in-
cluding accident/injury, admittance to an emergency department, 
attempted suicide, need for medical treatment, overnight stay in a 
hospital, outpatient surgery, and treatment of an accident/injury in 
an emergency department.
Analyses
To examine CPU and SPU patterns, descriptive cross tables were 
created for each kind of polydrug use (CPU, usual SPU, and maxi-
mum SPU). The associations of SPU with the aforementioned 
health factors were subsequently tested using linear regression 
analyses. However, although linear regression analyses were per-
formed, a causal relationship between SPU and health factors was 
not assessed. The aim of this study was to investigate their actual 
relationship. First, two models were created to test the association 
of SPU alone (usual SPU and maximum SPU) with the 7 factors 
considered as dependent variables (unadjusted models). We then 
took into account the effect of CPU (adjusted models). As SPU is 
part of CPU, we initially conducted linear regression analyses, with 
CPU as the predictor and SPU (usual SPU and maximum SPU) as 
the dependent variable, and then recorded the residual factors for 
each model. The residual factors were used as independent varia-
bles when analyzing each of the 7 health-related variables. This al-
lowed us to extract the unique variance of SPU and test the “pure” 
association of SPU with health. Holm-Bonferroni correction (37) 
was used, and statistical significance was set at 0.05. All analyses 
were conducted using SPSS software (version 20). Standardized 
regression slopes (β) were also presented instead of raw slopes to 
allow comparison between unadjusted and adjusted SPU with a 
scale-free estimation (38).
Results
Descriptive analysis
Prevalence rates and descriptive statistics are shown 
in Tables 1 and 2. On average, the participants used 
2.07 drugs for CPU (SD = 1.48), 1.46 drugs for usual SPU 
(SD = 1.03), and 1.84 drugs for maximum SPU (SD = 1.27). 
The most commonly used drugs included the following: 
alcohol (the most widely used substance, with 97.8% of 
participants drinking at least once during the past 12 
months, 81.0% drinking at least once simultaneously on a 
usual occasion, and 84.6% drinking at least once simulta-
neously on occasions where they combined a maximum of 
various drugs), tobacco (49.8% CPU, 44.0% to 56.5% SPU), 
and cannabis (32.1% CPU, 15.4% to 29.2% SPU). Crystal 
meth, heroin, ketamine, GHB/GBL, research chemicals, 
and spice were the least commonly used drugs (0.3% to 
0.5% CPU, 0.0% to 0.2% SPU).
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CPU and SPU patterns
Cross tables displaying the calculated CPU and maximum 
SPU values for each drug were presented. Cross tables 
were not presented for usual SPU because of the small 
sample size obtained for some drugs. The results for 
Table 1 Prevalence rates for each drug for CPU, usual SPU, and 
maximum SPU.
% of users
CPU Usual 
SPU
Maximum 
SPU
Alcohol 97.8 81.0 84.6
Tobacco 49.8 44.0 56.5
Cannabis 32.1 15.4 29.2
Hallucinogens/magic mushrooms 2.7 0.3 1.1
Other hallucinogens 2.3 0.5 1.3
Salvia divinorum 2.1 0.2 0.8
Speed 2.7 0.7 1.6
Amphetamine/methamphetamines 1.9 0.5 0.9
Crystal meth 0.3 0.1 0.1
Poppers 2.6 0.3 0.8
Inhalants 2.2 0.2 0.6
Ecstasy 3.8 1.1 2.6
Cocaine 3.3 0.9 2.4
Heroin 0.3 0.1 0.1
Ketamine 0.5 0.0 0.2
GHB/GBL 0.4 0.1 0.2
Research chemicals 0.3 0.0 0.1
Spice 0.5 0.0 0.1
For example, 97.8% of the participants used alcohol concurrently 
during the past 12 months, whereas only 0.5% used spice concur-
rently during the past 12 months. On a usual occasion, 81.0% of the 
participants drank alcohol simultaneously with another substance, 
and only 0.1% of them used heroin simultaneously with another 
substance.
CPU are shown in Table 3. Participants using only one 
drug, predominantly consumed alcohol (97.4%). When 
two types of drugs were used, it was most commonly 
alcohol (98.6%) and tobacco (78.3%). When three drugs 
were used, cannabis was added to alcohol and tobacco 
(94.3%). When four to seven types of drugs were used as 
CPU, hallucinogens (magic mushrooms, other hallucino-
gens, salvia divinorum), uppers (ecstasy, cocaine, speed 
amphetamines/methamphetamines), and sniffed drugs 
(poppers and solvents) were incorporated. Finally, when 
eight or more types of drugs were used, spice, crystal 
meth, heroin, GHB/GBL, research chemicals, and keta-
mine were the choice substances to be added. Commonly, 
these “later stage” drugs (i.e., spice, crystal meth, heroin, 
GHB/GBL, research chemicals, and ketamine) were added 
without replacing “early stage” drugs.
The results for maximum SPU were similar to CPU 
(Table 4). The first association was alcohol and tobacco 
(among the participants who reported the use of two 
drugs simultaneously, 98.7% used alcohol and 89.9% used 
tobacco), which were combined with cannabis when three 
types of drugs were used at the same time. When four to 
five types of drugs were used simultaneously, halluci-
nogens (magic mushrooms, other hallucinogens, salvia 
 divinorum), uppers (ecstasy, cocaine, speed ampheta-
mines/methamphetamines), and sniffed drugs (poppers 
and solvents) were added to those drugs already being 
used. Spice, crystal meth, heroin, GHB/GBL, research 
chemicals, and ketamine were incorporated when six or 
more types of drugs were used. As with CPU, if additional 
drugs were simultaneously used, then participants com-
monly added them without replacing other drugs that 
were already being used.
Associations of SPU with mental, social, and 
physical factors
The results for the models of usual and maximum SPU 
associations, with and without taking CPU into account, 
are shown in Table 5. In the unadjusted model, usual SPU 
was associated with all 7 dependent variables, whereas 
maximum SPU was associated with 6 out of the 7 depend-
ent variables. When participants used more substances 
simultaneously, they also felt more depressed (β = 0.124 to 
0.136, p < 0.001), anxious (β = 0.053 to 0.064, p < 0.001), and 
aggressive (β = 0.147 to 0.182, p < 0.001). In addition, they 
had a poorer state of mental health (β = –0.113 to –0.098, 
p < 0.001), and reported more negative social (β = 0.290 to 
0.304, p < 0.001) and health (β = 0.088 to 0.109, p < 0.001) con-
sequences. There was also a negative association between 
Table 2 Descriptive statistics for polydrug use and outcomes.
Mean SD
CPU (1–18) 2.07 1.48
SPU usual (0–18) 1.46 1.03
SPU maximum (0–18) 1.84 1.27
Social consequences (0–1) 0.22 0.21
Health consequences (0–1) 0.17 0.19
Depression (0–5) 0.69 0.70
Aggressiveness (0–1) 0.42 0.21
Anxiety (0–1) 0.20 0.20
Mental health (0–100)a 47.36 9.01
Physical health (0–100)a 53.11 6.26
Remarks: Ranges are given in brackets, SD: standard deviation.
aA higher score indicated better health, in contrast to the other 
 variables in the table. Here, 50 is the standardized mean.
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Table 4 Column percentages of each drug use according to the number of maximum SPU drug use.
Maximum SPU – number of drugs used
2
n = 1734
3
n = 1159
4
n = 153
5
n = 47
6
n = 40
7 and more
n = 36
Alcohol 98.7 99.1 98.7 97.9 97.5 94.4
Tobacco 89.9 98.4 98.0 95.7 97.5 94.4
Cannabis 10.5 95.7 90.8 100 97.5 100
Ecstasy 0.1 1.3 22.2 53.2 75.0 94.4
Cocaine 0.2 1.4 19.6 53.2 60.0 77.8
Hallucinogens/magic mushrooms 0.1 0.5 14.4 10.6 17.5 44.4
Others hallucinogens 0.1 0.5 12.4 14.9 27.5 61.1
Salvia divinorum 0.0 0.3 13.1 12.8 10.0 25.0
Poppers 0.2 0.7 12.4 10.6 10.0 13.9
Speed 0.1 0.7 5.9 25.5 67.5 72.2
Solvent sniffing 0.1 1.1 5.2 4.3 7.5 13.9
Amphetamine/methamphetamines 0.1 0.1 2.6 14.9 22.5 69.4
GHB/GBL 0.0 0.0 0.7 0.0 5.0 22.2
Research chemicals 0.0 0.1 1.3 0.0 2.5 8.3
Ketamine 0.0 0.1 2.0 2.1 2.5 13.9
Spice 0.1 0.1 0.7 2.1 0.0 11.1
Crystal meth 0.1 0.0 0.0 0.0 0.0 5.6
Heroin 0.0 0.0 0.0 2.1 0.0 16.7
For example, among the participants who used 2 drugs simultaneously (n = 1734), 98.7% drank alcohol, 89.9% smoked tobacco, 10.5% used 
cannabis, 0.2% used cocaine, 0.2% used poppers, and 0.1% used ecstasy, hallucinogens such as magic mushrooms, other hallucinogens, 
speed, solvent, amphetamines/methamphetamines, spice, and crystal meth.
Table 3 Percentages of each drug use according to the number of CPU.
CPU – number of drugs used
1
n = 2341
2
n = 1459
3
n = 1077
4
n = 199
5
n = 72
6
n = 58
7
n = 39
8
n = 22
9 and more
n = 52
Alcohol 97.4 98.6 99.9 98.5 100 100 100 100 94.2
Tobacco 2.2 78.3 96.5 98.0 97.2 96.6 97.4 100 90.4
Cannabis 0.3 19.5 94.3 91.5 98.6 94.8 92.3 100 86.5
Poppers 0.0 1.3 1.8 19.6 20.8 22.4 17.9 13.6 42.3
Hallucinogens/magic mushrooms 0.0 0.3 0.8 17.1 23.6 34.5 43.6 40.9 69.2
Salvia divinorum 0.0 0.2 0.5 17.1 19.4 13.8 30.8 31.8 61.5
Ecstasy 0.0 0.1 0.9 14.1 33.3 63.8 74.4 100 96.2
Cocaine 0.0 0.1 1.1 12.1 33.3 55.2 59.0 59.1 90.4
Solvent sniffing 0.0 1.4 2.4 11.6 20.8 17.2 12.8 9.1 28.8
Speed 0.0 0.0 0.8 6.5 16.7 36.2 61.5 68.2 94.2
Other hallucinogens 0.0 0.1 0.3 3.5 15.3 37.9 46.2 77.3 82.7
Amphetamine/methamphetamines 0.0 0.0 0.2 5.5 13.9 13.8 41.0 54.5 84.6
Spice 0.0 0.1 0.1 1.5 2.8 6.9 7.7 4.5 19.2
Chrystal meth 0.0 0.1 0.1 0.0 1.4 0.0 2.6 13.6 19.2
Heroin 0.0 0.0 0.0 0.5 1.4 0.0 0.0 4.5 25.0
GHB/GBL 0.0 0.0 0.2 1.0 0.0 1.7 0.0 13.6 28.8
Research chemicals 0.0 0.0 0.1 1.0 0.0 3.4 5.1 4.5 19.2
Ketamine 0.0 0.0 0.0 1.0 1.4 1.7 7.7 4.5 34.6
For example, among the participants who used 1 drug concurrently (n = 2341), 97.4% drank alcohol, 2.2% smoked tobacco, 0.3% used can-
nabis, and 0.1% used solvent.
physical health and usual SPU (β = –0.052, p < 0.001). In 
the adjusted models, SPU also had an additive associa-
tion with aggressiveness (β = 0.058 to 0.115, p < 0.001) and 
negative social consequences (β = 0.098 to 0.110, p < 0.001). 
However, SPU was no longer negatively associated with 
depression, anxiety, health consequences, or mental/
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physical health. The remaining associations were not as 
strong as those of the unadjusted models (e.g., aggressive-
ness: β = 0.147 for maximum SPU and β = 0.058 for residuals 
of maximum SPU).
Discussion
Patterns of CPU and SPU
This study investigated the patterns of CPU and SPU by 
examining separate cross tables for CPU and maximum 
SPU with each drug. The results indicated that drugs 
were commonly added for both CPU and maximum SPU. 
When participants increased the number of drugs they 
were using, they usually did not replace one drug with 
another. Instead, they added more drugs to those that 
were already in use. The order in which drugs were added 
resembled the sequential drug use patterns described in 
previous studies, with licit drugs (alcohol and tobacco) 
used initially, followed by cannabis and then other illicit 
drugs (39–42). Apart from cannabis, the use of two dis-
tinct classes of illicit drugs was identified. The drugs used 
first included hallucinogens (magic mushrooms), other 
hallucinogens (LSD or salvia divinorum), uppers (speed, 
ecstasy, cocaine, amphetamines, or methamphetamines), 
and sniffed drugs (poppers or solvents). The use of these 
substances was followed by use of other “hard” drugs, 
such as ketamine, heroin, GHB/GBL, research chemicals, 
crystal meth, and spice. In fact, it appeared that there was 
an escalation in the types of illicit drugs being used. In 
other words, the number of drugs used can be consid-
ered as an indicator of the severity of polydrug use. This 
result supported the use of “total number of drugs” as a 
relevant variable, as an increasing number of drugs added 
information (i.e., additional drugs to those already used), 
but was not something qualitatively different (e.g., other 
drugs instead of those already used).
Associations of SPU with mental, social, and 
physical factors
Regression analyses showed that CPU was a confounding 
variable for SPU. When the models were not adjusted for 
CPU, SPU showed an association with all factors related 
to mental, social, and physical consequences (except 
physical health with SPU maximum). When the variance 
between CPU and SPU was taken into account, the only 
remaining associations were aggressiveness and negative 
social consequences (for both usual and maximum SPU). 
In other words, the number of drugs used concurrently 
had an important association with health factors. This 
agreed with results reported in previous studies (15–18). 
Aggressiveness and social consequences are interrelated. 
Therefore, this finding might also suggest that only SPU 
can display this independent association among a sub-
group of individuals prone to these types of behavioral 
disorders. There was no significant association between 
SPU and depression, anxiety, or mental/physical health 
consequences when CPU was taken into account. These 
results were interesting as they may indicate that users 
understood the pharmacology of the drugs they used, 
combining them intentionally to reduce undesired effects 
(20, 43, 44). Indeed, some associations are well known 
[e.g., alcohol reduces the discomfort of coming down 
from cocaine (26, 45), and cocaine attenuates the negative 
effects of alcohol (26)]. In addition, heroin can be used 
when coming down from cocaine to attenuate its anxio-
genic effects, whereas cocaine can be used to temper 
the depressive effects of heroin (46). Thus, the absence 
Table 5 Standardized slopes (β) of regression analyses for unadjusted and adjusted models of health issues on SPU.
Outcomes SPU (unadjusted) Residuals from CPU models (adjusted)
Usual
β (SE)
Maximum
β (SE)
Usual
β (SE)
Maximum
β (SE)
Social consequences 0.290 (0.003)a 0.304 (0.002)a 0.110 (0.004)a 0.098 (0.003)a
Health consequences 0.088 (0.014)a 0.109 (0.14)a 0.011 (0.013) 0.025 (0.014)
Aggressiveness 0.182 (0.014)a 0.147 (0.014)a 0.115 (0.014)a 0.058 (0.014)a
Anxiety 0.064 (0.014)a 0.053 (0.014)a 0.021 (0.014) –0.004 (0.013)
Physical health –0.052 (0.014)a –0.034 (0.014) –0.020 (0.014) 0.012 (0.013)
Mental health –0.098 (0.014)a –0.113 (0.014)a –0.011 (0.014) –0.013 (0.014)
Depression 0.124 (0.014)a 0.136 (0.014)a 0.021 (0.014) 0.014 (0.013)
Remarks: Standardized standard errors (SE) are given in parentheses.
ap < 0.001; p-values with a Holm-Bonferroni correction are given.
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of association between SPU and depression, anxiety, or 
mental health may be explained by users’ intention to 
combine drugs in order to avoid particular detrimental 
effects, such as depression and anxiety. Other explana-
tions could be that the number of drugs used accounts 
for associations with health/consequences, and that 
combined simultaneous use does not add more to this 
association. This would mean that measuring the solely 
number of drugs used, and not necessarily their simul-
taneous use, may be sufficient in substance use surveys. 
Further investigations must be conducted to test these 
two hypotheses.
Limitations
The main limitation of this study was its cross-sectional 
design, which did not allow a conclusion to be made on 
whether polydrug use was a cause or a consequence of 
health, mental, and social problems, as is often the case 
in these types of studies (47, 48). However, C-SURF is a lon-
gitudinal study, and future analyses must focus on study-
ing the effect of past drug use on current psychological 
distress. Another limitation of our study was that it did not 
include female participants. Thus, associations between 
polydrug use and health factors should be studied in a 
sample of women, in order to assess the potential differ-
ences between men and women with regard to these find-
ings. A third limitation involved the use of a personality 
scale to assess anxiety and aggressiveness. Although this 
scale can be employed to examine the level of anxiety or 
aggressiveness at a given time point, further studies using 
questions more closely related to psychological health or 
distress are needed.
Conclusion
We demonstrated that the pattern of CPU and SPU within a 
sample of young adult men followed previously described 
stages of drug use, which involved the sequential use of 
alcohol, tobacco, cannabis, and then other illicit drugs. 
In addition, two distinct classes of illicit drugs were iden-
tified. The first class included uppers, hallucinogens 
and sniffed drugs, whereas the second class included 
ketamine, heroin, GHB/GBL, research chemicals, crystal 
meth, and spice. As the users progressed along this 
sequence of drug use, they did not stop taking any of the 
drugs that they were already using. Hence, the number 
of drugs used can be seen as a proxy of the severity of 
polydrug use.
The additive effect of SPU on CPU was also assessed 
in this study. Previous reports indicated that SPU can be 
distinguished from CPU. Thus, even though these two 
concepts were linked, they remained discriminable con-
structs (19). Consistent with this idea, we found that SPU 
was independently associated with social factors, includ-
ing aggressiveness and negative social consequences 
among young men. However, we did not observe any rel-
evant associations with some specific outcomes related to 
mental health, such as depression or anxiety.
Received May 21, 2013; accepted July 4, 2013; previously published 
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